{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:11:42Z","timestamp":1788300702361,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Nanotechnology Research Center, Mashhad University of Medical Sciences"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.actatropica.2019.05.018","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T11:25:51Z","timestamp":1558005951000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB\/c mice"],"prefix":"10.1016","volume":"196","author":[{"given":"Zahra","family":"Kavian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Hoda","family":"Alavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Golmohamadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-6828","authenticated-orcid":false,"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actatropica.2019.05.018_bib0005","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00809-10","article-title":"Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis","volume":"54","author":"Aguiar","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","article-title":"Targeting to macrophages: role of physicochemical properties of particulate carriers\u2014liposomes and microspheres\u2014on the phagocytosis by macrophages","volume":"79","author":"Ahsan","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.trstmh.2008.05.015","article-title":"Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis","volume":"102","author":"Ansari","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4269\/ajtmh.2001.65.466","article-title":"Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala","volume":"65","author":"Arana","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of america (IDSA) and the american society of tropical medicine and hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4269\/ajtmh.1995.53.648","article-title":"A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran","volume":"53","author":"Asilian","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0040","first-page":"353","article-title":"Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran","volume":"81","author":"Asilian","year":"2003","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27170-1","article-title":"Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania","volume":"8","author":"Baranwal","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0050","first-page":"301","article-title":"Optimizing efficacy of Amphotericin B through nanomodification","volume":"2","author":"Barratt","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.actatropica.2012.06.004","article-title":"Colloidal, in vitro and in vivo anti-leishmanial l properties of transfersomes containing paromomycin sulfate in susceptible BALB\/c mice","volume":"124","author":"Bavarsad","year":"2012","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0060","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0065","first-page":"252","article-title":"Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation","volume":"7","author":"Bhatia","year":"2004","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0070","first-page":"1094","article-title":"Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B","volume":"40","author":"Bhattacharya","year":"2016","journal-title":"FUNGISOME"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/exd.13098","article-title":"Topical treatment with a two-component gel releasing nitric oxide cures C57BL\/6 mice from cutaneous leishmaniasis caused by Leishmania major","volume":"25","author":"Butsch","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0085","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/jac\/dks220","article-title":"Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro","volume":"67","author":"Das","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1590\/S0102-311X2000000400013","article-title":"The epidemiology and control of leishmaniasis in Andean countries","volume":"16","author":"Davies","year":"2000","journal-title":"Cad. Saude Publica"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-3083.2009.03100.x","article-title":"Liposomes in dermatology today","volume":"23","author":"De Leeuw","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0100","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0105","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/jac\/dks164","article-title":"Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0738-081X(96)00058-2","article-title":"Cutaneous leishmaniasis: clinical aspect","volume":"14","author":"Dowlati","year":"1996","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2008.05.002","article-title":"Liposomes and skin: from drug delivery to model membranes","volume":"34","author":"El Maghraby","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","article-title":"Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH (3)(edelfosine) and amphotericin B","volume":"81","author":"Escobar","year":"2002","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0125","first-page":"191","article-title":"Evaluation of miltefosine against leishmania major (mrho\/ir\/75\/er) &58; in vitro and in vivo studies","volume":"46","author":"Esmaeili","year":"2008","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0130","article-title":"Drug resistance in eukaryotic microorganisms","volume":"1","author":"Fairlamb","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0135","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.42.12.3092","article-title":"Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B","volume":"42","author":"Frankenburg","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0140","first-page":"538","article-title":"Topical treatment for cutaneous leishmaniasis","volume":"3","author":"Garnier","year":"2002","journal-title":"Curr. Opin. Investig. Drugs (London, England: 2000)"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1211\/jpp.59.1.0006","article-title":"Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis","volume":"59","author":"Garnier","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0150","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0155","first-page":"75","article-title":"Liposomes from vegetable phosphatidylcholine: their production and effects on the skin","volume":"109","author":"Ghyczy","year":"1994","journal-title":"Cosmet. Toiletr."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eri.10.19","article-title":"Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Goto","year":"2010","journal-title":"Expert Rev. Anti. Ther."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4269\/ajtmh.11-0812","article-title":"Drug discovery algorithm for cutaneous leishmaniasis","volume":"88","author":"Grogl","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0170","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijpara.2003.11.021","article-title":"The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds","volume":"34","author":"Gumy","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1039\/C5CS00674K","article-title":"New approaches from nanomedicine for treating leishmaniasis","volume":"45","author":"Guti\u00e9rrez","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30040-5","article-title":"Importance of secondary screening with clinical isolates for anti-leishmanial drug discovery","volume":"8","author":"Hefnawy","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150185","article-title":"Ultradeformable archaeosomes for needle free nanovaccination with leishmania braziliensis antigens","volume":"11","author":"Higa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0168-3659(99)00272-2","article-title":"In vivo EPR of topical delivery of a hydrophilic substance encapsulated in multilamellar liposomes applied to the skin of hairless and normal mice","volume":"66","author":"Honzak","year":"2000","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0195","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1002\/ange.200900111","article-title":"Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery","volume":"121","author":"Huang","year":"2009","journal-title":"Angew. Chemie"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2011.01.044","article-title":"Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin B","volume":"408","author":"Iman","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actatropica.2017.02.019","article-title":"Nanopharmaceuticals as a solution to neglected diseases: Is it possible?","volume":"170","author":"Islan","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0210","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","article-title":"Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice","volume":"53","author":"Jaafari","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmech.2018.08.012","article-title":"An update on small molecule strategies targeting leishmaniasis","volume":"157","author":"Kapil","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0220","first-page":"e8","article-title":"Cutaneous Leishmania tropica in children: report of three imported cases successfully treated with liposomal amphotericin B","volume":"32","author":"Kn\u00f6pfel","year":"2018","journal-title":"JEADV"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0225","article-title":"Promising nanotherapy in treating leishmaniasis","author":"Marins","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jlb.47.2.187","article-title":"Macrophage\u2010parasite interactions in leishmania infections","volume":"47","author":"Mau\u00ebl","year":"1990","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.2042-7158.1998.tb03304.x","article-title":"Biopharmaceutics: topical delivery of keloid therapeutic drug, Tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats","volume":"50","author":"Murakami","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0240","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dth.12377","article-title":"Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report","volume":"29","author":"Mushtaq","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0245","first-page":"15","article-title":"Anthroponotic cutaneous leishmaniasis in the city of bam, southeast Iran","volume":"24","author":"Nadim","year":"1995","journal-title":"Iran. J. Public Health"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0250","first-page":"5","article-title":"Nanoliposomal miltefosine for the treatment of cutaneous leishmaniasis caused by Leishmania major (MRHO\/IR\/75\/ER): the drug preparation and in vitro study","author":"Najafian","year":"2016","journal-title":"Int. J. Pharm. Res. Allied Sci."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2018.05.002","article-title":"Investigation of anti-leishmanial l efficacy of miltefosine and ketoconazole loaded on nanoniosomes","author":"Nazari-Vanani","year":"2018","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.colsurfb.2015.12.003","article-title":"Topical amphotericin B in ultradeformable liposomes: formulation, skin penetration study, antifungal and antileishmanial activity in vitro","volume":"139","author":"Perez","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0265","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00403-011-1166-4","article-title":"Liposomal systems as drug delivery vehicles for dermal and transdermal applications","volume":"303","author":"Pierre","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(99)90192-X","article-title":"Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis","volume":"93","author":"Schmidt-Ott","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"Scott","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0285","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/AAC.00505-09","article-title":"Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0290","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0295","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001813-200011000-00006","article-title":"Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients","volume":"11","author":"Smorenburg","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0300","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.trstmh.2006.02.022","article-title":"Treatment of New World cutaneous leishmaniasis with miltefosine","volume":"100","author":"Soto","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinids\/20.1.47","article-title":"Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin\/methylbenzethonium chloride and injectable meglumine antimonate","volume":"20","author":"Soto","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0310","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","article-title":"Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0315","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0320","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian mucosal leishmaniasis with miltefosine","volume":"44","author":"Soto","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0325","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4269\/ajtmh.2008.78.210","article-title":"Efficacy of miltefosine for Bolivian cutaneous leishmaniasis","volume":"78","author":"Soto","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0330","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","article-title":"Short-course of oral miltefosine for treatment of visceral leishmaniasis","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0335","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0340","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","article-title":"Oral miltefosine for the treatment of Indian visceral leishmaniasis","volume":"100","author":"Sundar","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0345","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jphp.12548","article-title":"Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB\/c mouse model","volume":"68","author":"Van Bocxlaer","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0350","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/AAC.48.8.3010-3015.2004","article-title":"Possible mechanism of miltefosine-mediated death of Leishmania donovani","volume":"48","author":"Verma","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0355","series-title":"Application for inclusion of Miltefosine on WHO Model List of Essential Medicines","author":"Vinson","year":"2010"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0360","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.4049\/jimmunol.0803859","article-title":"Miltefosine promotes IFN-gamma-dominated anti-leishmanial l immune response","volume":"182","author":"Wadhone","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for african visceral leishmaniasis: phase II randomized trial","volume":"10","author":"Wasunna","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0370","series-title":"World Health Organization","author":"WHO","year":"2018"},{"key":"10.1016\/j.actatropica.2019.05.018_bib0375","first-page":"02009","article-title":"Ambisome\u00ae treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy","author":"Wijnant","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0380","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00358-17","article-title":"Efficacy of a paromomycin plus chloroquine combination therapy in experimental cutaneous leishmaniasis","author":"Wijnant","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.05.018_bib0385","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X18310738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X18310738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T19:51:59Z","timestamp":1562961119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X18310738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":77,"alternative-id":["S0001706X18310738"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2019.05.018","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2019.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}